{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:27:42Z","timestamp":1792301262704,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.phrs.2022.106336","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T02:11:57Z","timestamp":1656555117000},"page":"106336","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"182","author":[{"given":"Yaxin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuening","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenshan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixin","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106336_bib1","unstructured":"WHO, Global Tuberculosis Report 2020, in: Organization GWH, (Ed.)World Health Organization, Geneva, 2020."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082235","article-title":"Association between HIV\/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis","volume":"9","author":"Mesfin","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib3","first-page":"45","article-title":"Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City","volume":"10","author":"Quy","year":"2006","journal-title":"Vietnam. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2022.106336_bib4","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/518665","article-title":"HIV infection and multidrug-resistant tuberculosis: the perfect storm","volume":"196","author":"Wells","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"9728","key":"10.1016\/j.phrs.2022.106336_bib5","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047370","article-title":"Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review","volume":"7","author":"Arentz","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2022.106336_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.phrs.2022.106336_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.phrs.2022.106336_bib9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB--Final Study Outcomes","volume":"373","author":"Lee","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2022.106336_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.phrs.2022.106336_bib12","doi-asserted-by":"crossref","unstructured":"Moola S., Munn Z., Tufanaru C., Aromataris E., Sears K., Sfetcu R., Currie M., Lisy K., Qureshi R., Mattis P, M.P. , Chapter 7: systematic reviews of etiology and risk, in: JBI Manual for Evidence Synthesis, JBI, 2020. \u3008http's:\/\/synthesismanual.jbi.global\/\u3009.","DOI":"10.46658\/JBIRM-17-06"},{"issue":"6","key":"10.1016\/j.phrs.2022.106336_bib13","first-page":"640","article-title":"Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis","volume":"9","author":"Laserson","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"10.1016\/j.phrs.2022.106336_bib14","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update, World Health Organization Copyright \u00a9 2011, World Health Organization,\u00a0Geneva, 2011."},{"key":"10.1016\/j.phrs.2022.106336_bib15","unstructured":"WHO, Rapid communication\uff1akey changes to treatment of multidru- and rifampicin-resistant tuberculosis(MDR\/RR-TB), in: WHO\/CDS\/TB\/2018, (Ed.), World Health Organization, 2018.Organization, Geneva, 2018."},{"key":"10.1016\/j.phrs.2022.106336_bib16","doi-asserted-by":"crossref","unstructured":"M. Borenstein, L.V. Hedges, J.P.T. Higgins, H.R. Rothstein. Introduction to Meta-Analysis, 2009.","DOI":"10.1002\/9780470743386"},{"issue":"4","key":"10.1016\/j.phrs.2022.106336_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106336_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol. Methods"},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01181-2019","article-title":"A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis","volume":"55","author":"Olayanju","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib21","doi-asserted-by":"crossref","DOI":"10.5588\/ijtld.17.0498","article-title":"Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries","volume":"22","author":"Trebucq","year":"2018","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"8","key":"10.1016\/j.phrs.2022.106336_bib22","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/cid\/cix1125","article-title":"Improved survival and cure rates with concurrent treatment for multidrug-resistant tuberculosis-human immunodeficiency virus coinfection in South Africa","volume":"66","author":"Brust","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2022.106336_bib23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/QAI.0000000000001833","article-title":"Effect of antiretroviral therapy on treatment outcomes in a prospective study of extensively drug-resistant tuberculosis (XDR-TB) HIV coinfection treatment in KwaZulu-Natal, South Africa","volume":"79","author":"Yuengling","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.phrs.2022.106336_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5588\/ijtld.14.0369","article-title":"Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa","volume":"19","author":"Loveday","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"12","key":"10.1016\/j.phrs.2022.106336_bib25","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/thoraxjnl-2015-207374","article-title":"Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study","volume":"70","author":"Meressa","year":"2015","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.phrs.2022.106336_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028066","article-title":"Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India","volume":"6","author":"Isaakidis","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2022.106336_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020436","article-title":"Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence","volume":"6","author":"Farley","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2022.106336_bib28","first-page":"420","article-title":"Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa","volume":"14","author":"Heller","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib30","first-page":"61","article-title":"Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis","volume":"111","author":"Misra","year":"2021","journal-title":"Samj South Afr. Med. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib31","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-020-4887-1","article-title":"Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study","volume":"20","author":"Van","year":"2020","journal-title":"BMC Infect. Dis."},{"issue":"9","key":"10.1016\/j.phrs.2022.106336_bib32","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/cid\/ciy727","article-title":"Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug-resistant tuberculosis: a retrospective cohort study","volume":"68","author":"Zhao","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.5588\/ijtld.20.0082","article-title":"Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini","volume":"24","author":"Vambe","year":"2020","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"10.1016\/j.phrs.2022.106336_bib34","article-title":"Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high HIV burden rural South Africa: a retrospective cohort analysis","author":"Tack","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.phrs.2022.106336_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100268","article-title":"Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries","volume":"20","author":"Schw\u0153bel","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.phrs.2022.106336_bib36","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.5588\/ijtld.18.0205","article-title":"Treatment outcomes of pre- and extensively drug-resistant tuberculosis in Johannesburg","volume":"22","author":"Nkurunziza","year":"2018","journal-title":"South Afr. Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205601","article-title":"Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in eSwatini (formerly Swaziland), 2011-2013","volume":"13","author":"Verdecchia","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193491","article-title":"Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: multicenter cohort study","volume":"13","author":"Bastard","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2022.106336_bib39","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4103\/ijmy.ijmy_140_18","article-title":"Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis\/HIV coinfected patients with drug-resistant tuberculosis","volume":"7","author":"Azeez","year":"2018","journal-title":"Int. J. Mycobacteriol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106336_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.phrs.2022.106336_bib41","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00544-2018","article-title":"Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa","volume":"51","author":"Olayanju","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.phrs.2022.106336_bib42","first-page":"17","article-title":"Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine","author":"Aibana","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/QAI.0000000000001169","article-title":"High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006-2013","volume":"74","author":"Shin","year":"2017","journal-title":"Jaids J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144249","article-title":"Tuberculosis case fatality and other causes of death among multidrug-resistant tuberculosis patients in a high HIV prevalence setting, 2000-2008, South Africa","volume":"11","author":"van der Walt","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib45","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.5588\/ijtld.15.0915","article-title":"Treatment outcomes of drug-resistant tuberculosis patients in Kenya","volume":"20","author":"Mibei","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.phrs.2022.106336_bib46","first-page":"15","article-title":"Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa","author":"Umanah","year":"2015","journal-title":"BMC Infect. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142873","article-title":"Time to ART initiation among patients treated for rifampicin-resistant tuberculosis in Khayelitsha, South Africa: impact on mortality and treatment success","volume":"10","author":"Daniels","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2022.106336_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/trstmh\/trv037","article-title":"Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa","volume":"109","author":"Mohr","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib49","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/infdis\/jiu040","article-title":"Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests","volume":"209","author":"Zetola","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2022.106336_bib50","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.5588\/pha.14.0042","article-title":"Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus","volume":"4","author":"Khaliaukin","year":"2014","journal-title":"Public Health Action"},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3201\/eid1903.120998","article-title":"Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection","volume":"19","author":"O\u2019Donnell","year":"2013","journal-title":"Emerg. Infect. Dis."},{"issue":"9","key":"10.1016\/j.phrs.2022.106336_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073975","article-title":"Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa","volume":"8","author":"Brust","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046943","article-title":"Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho","volume":"7","author":"Satti","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib54","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3201\/eid2310.170468","article-title":"Six-month response to delamanid treatment in MDR TB patients","volume":"23","author":"Hewison","year":"2017","journal-title":"Emerg. Infect. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106336_bib55","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.5588\/ijtld.20.0048","article-title":"Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid","volume":"24","author":"Padayatchi","year":"2020","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"1","key":"10.1016\/j.phrs.2022.106336_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-05967-2","article-title":"Risk factors for mortality among patients diagnosed with multi-drug resistant tuberculosis in Uganda- a case-control study","volume":"21","author":"Kizito","year":"2021","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5588\/ijtld.11.0473","article-title":"HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era","volume":"16","author":"Palacios","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"11","key":"10.1016\/j.phrs.2022.106336_bib58","doi-asserted-by":"crossref","first-page":"88S","DOI":"10.3855\/jidc.11979","article-title":"Treatment outcomes of drug-resistant tuberculosis in people living with HIV in Odesa province, Ukraine, 2014-2016","volume":"14","author":"Yesypenko","year":"2020","journal-title":"J. Infect. Dev. Ctries."},{"key":"10.1016\/j.phrs.2022.106336_bib59","unstructured":"WHO. Consolidated Guidelines on Drug-resistant Tuberculosis Treatment, In, 2019."},{"key":"10.1016\/j.phrs.2022.106336_bib60","unstructured":"W.H. Organzation, Roadmap to Implement the Tuberculosis Action Plan for the WHO European Region 2016\u20132020: Towards Ending Tuberculosis and Multidrug-resistant Tuberculosis. World Health Organization, 27 August 2020."},{"issue":"5","key":"10.1016\/j.phrs.2022.106336_bib61","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.phrs.2022.106336_bib62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","article-title":"Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study","volume":"6","author":"Schnippel","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106336_bib63","doi-asserted-by":"crossref","first-page":"E201","DOI":"10.1016\/S2352-3018(19)30035-9","article-title":"Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection","volume":"6","author":"O\u2019Donnell","year":"2019","journal-title":"Lancet HIV"},{"issue":"10150","key":"10.1016\/j.phrs.2022.106336_bib64","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.phrs.2022.106336_bib65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.5588\/ijtld.18.0822","article-title":"Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis","volume":"23","author":"Lifan","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"issue":"9","key":"10.1016\/j.phrs.2022.106336_bib66","doi-asserted-by":"crossref","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","article-title":"Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural south africa: a retrospective cohort analysis","volume":"73","author":"Tack","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.phrs.2022.106336_bib67","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in: WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment, World Health Organization \u00a9 World Health Organization 2020."},{"key":"10.1016\/j.phrs.2022.106336_bib68","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in: Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, World Health Organization Copyright \u00a9 World Health Organization 2016."},{"issue":"16","key":"10.1016\/j.phrs.2022.106336_bib69","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":"Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis","volume":"365","author":"Blanc","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2022.106336_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25772","article-title":"What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis","volume":"24","author":"Burke","year":"2021","journal-title":"J. Int. AIDS Soc."},{"issue":"6","key":"10.1016\/j.phrs.2022.106336_bib71","first-page":"670","volume":"14","author":"Li","year":"2021","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.phrs.2022.106336_bib72","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in: Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis, World Health Organization Copyright \u00a9 World Health Organization 2014."},{"issue":"2","key":"10.1016\/j.phrs.2022.106336_bib73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ijantimicag.2016.10.020","article-title":"Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir\/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis","volume":"49","author":"Brill","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"8","key":"10.1016\/j.phrs.2022.106336_bib74","doi-asserted-by":"crossref","first-page":"969","DOI":"10.5588\/ijtld.15.0123","article-title":"Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis","volume":"19","author":"Isaakidis","year":"2015","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."},{"key":"10.1016\/j.phrs.2022.106336_bib75","unstructured":"WHO, Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis, in: W.H. Organization, (Ed.),\u00a0World Health Organization,"},{"issue":"8","key":"10.1016\/j.phrs.2022.106336_bib76","doi-asserted-by":"crossref","first-page":"998","DOI":"10.5588\/ijtld.11.0713","article-title":"Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care","volume":"16","author":"Brust","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182200281X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182200281X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:42:29Z","timestamp":1760913749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182200281X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":76,"alternative-id":["S104366182200281X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106336","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106336","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106336"}}